CollPlant Biotechnologies Ltd. Sponsored ADR

CLGN Healthcare Biotechnology

CollPlant Biotechnologies Ltd. Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $2.4 million, up 360.4% from fiscal 2024. In the quarter to June 2026, revenue fell 39.7%, EPS grew 32.5% and free cash flow grew 5.08%, each against the same quarter a year earlier.

3.60 0.08 −2.17%
Market cap
$7.0M
P/E
0.0×
Fwd P/E
−0.7×
Dividend yield
—
F-score
4/9
Altman Z
−16.87
Beneish M
−3.20
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
Piotroski F-Score

+8 more TTM periods

4 4 2 2
ROE
(92.74%) (117.56%) (151.99%) (161.98%)
ROA
(66.57%) (77.90%) (99.53%) (101.59%)
ROIC
(1,612.55%) (5,478.53%) (3,125.00%) 0.00%
Return on Tangible Assets
(140.76%) (207.46%) (300.55%) (509.49%)
Average Days of Receivables
37.46 34.48 218.62 464.86
Free Cash Flow per Share
(7.87) (7.74) (8.24) (7.76)
Free Cash Flow
(10.02) (9.45) (11.33) (11.20)
Other line items

Show all line items

Columns are period end dates · fundamentals updated 6 Oct 2026